Members Only Content
Subscribe to get full access
Free Preview
The drug developer is exploiting the diverse functionality of CRISPR with an "anything goes" strategy to clinical development. That's both risky and rewarding.
Upstart Recommendation Report Upstart Presentation Slides
Lemonade (NYSE: LMND) is a new player who's really adding zest to the insurance industry. Its AI-powered underwriting enables it to [...]
PubMatic just reported first quarter 2025 results. Aside from the headwinds of a DSP partner changing its bidding process, the [...]
